The human STING agonist E7766 induces immunogenic tumor clearance, independent of tumor-intrinsic STING expression in the <i>KRAS^G12D/+ Trp53^-/-</i> murine model of sarcoma.

ABSTRACT: Soft tissue sarcomas (STS) are aggressive high-fatality cancers that affect children and adults. Most STS subtypes harbor an immunosuppressive tumor microenvironment (TME) and respond poorly to immunotherapy. Therapies capable of dismantling the immunosuppressive TME are needed to improve sensitivity to emerging immunotherapies. Activation of the Stimulator of INterferon Genes (STING) pathway has shown promising anti-tumor effects in preclinical models of carcinoma, but evaluations in sarcoma are lacking. Herein, we sought to examine the immune modulation and therapeutic efficacy of three translational small molecule STING agonists in an immunologically cold model of STS. Three classes of STING agonists, ML RR-S2 CDA, MSA-2, and E7766 were evaluated in an orthotopic KrasG12D/+ Trp53-/- mod

SUBMITTER: Hildebrand KM 

PROVIDER: S-EPMC12296111 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature